Argus Downgrades Pfizer Stock to Hold Amid Topline Growth Concerns
Friday, 22 March 2024, 13:41
Argus Cuts Pfizer to Hold
Reasons for Downgrade
- Concerns about Topline Growth: Argus is worried about Pfizer's ability to grow revenue significantly.
Argus has recently downgraded Pfizer stock to Hold from Buy. The move comes as the financial firm expresses concerns about Pfizer's future revenue growth, calling attention to the need for closer monitoring of Pfizer's performance in the coming months.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.